Sugi Predict

Sugi Predict / Compounds / SCHEMBL976030

SCHEMBL976030

SCHEMBL976030

C[C@@H](O)C[C@@H](O)CC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC22A6 Q4U2R8 1/20 0.60
▸ GABRR1 P24046 2/20 0.50
▸ MAPT P10636 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ GPR84 Q9NQS5 4/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CACNA2D1 P54289 2/20 0.41
▸ CACNB3 P54284 1/20 0.41
▸ CACNA1C Q13936 1/20 0.41
▸ PGR P06401 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ CACNA2D2 Q9NY47 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.38
▸ TP53 P04637 1/20 0.36
▸ HMGCR P04035 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8292735 1.00 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL976447 1.00 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL667024 0.84 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL4748781 0.84 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL6453593 0.83 SLC22A6 (0.75) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL16600216 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL19615565 0.80 SLC22A6 (0.36) SLC22A6GABRR1MAPTLMNASMN1; SMN2
SCHEMBL14189817 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL13701365 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL28670099 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112662637-B Formate dehydrogenase mutant and preparation method and application thereof 江苏阿尔法药业股份有限公司 2022-11-11 — — CN claimed
CN-112662637-A Formate dehydrogenase mutant and preparation method and application thereof 江苏阿尔法药业有限公司 2021-04-16 — — CN claimed
CN-118956793-B Formate dehydrogenase mutant and application thereof 天津凯莱英生物科技有限公司 2025-02-25 — — CN disclosed
CN-118956793-A Formate dehydrogenase mutant and application thereof 天津凯莱英生物科技有限公司 2024-11-15 — — CN disclosed
CN-112662637-B Formate dehydrogenase mutant and preparation method and application thereof 江苏阿尔法药业股份有限公司 2022-11-11 — — CN disclosed
CN-112662637-B Formate dehydrogenase mutant and preparation method and application thereof 江苏阿尔法药业股份有限公司 2022-11-11 — — CN disclosed
CN-112662637-A Formate dehydrogenase mutant and preparation method and application thereof 江苏阿尔法药业有限公司 2021-04-16 — — CN disclosed
CN-112662637-A Formate dehydrogenase mutant and preparation method and application thereof 江苏阿尔法药业有限公司 2021-04-16 — — CN disclosed
US-20130296561-A1 PROCESS FOR THE PREPARATION OF STATINS IN THE PRESENCE OF BASE DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2013-11-07 — — US disclosed
US-20130131088-A1 TREATING CANCER WITH STATINS AND COMPOUNDS HAVING DIPYRIDAMOLE ACTIVITY UNIVERSITY HEALTH NETWORK (CA) 2013-05-23 — — US disclosed
US-8148324-B2 Aldolases, nucleic acids encoding them; improving thermal stability of enzyme; biosynthesis of atorvastatin, rosuvastatin, fluvastatin starting from e.g. acetaldehyde and chloroacetaldehyde, using enzyme 2-deoxyribose-5-phosphate aldolase (DERA) to form pyran intermediate VERENIUM CORPORATION (US) 2012-04-03 — — US disclosed
US-20110009593-A1 Polymeric Bioplastics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-01-13 — — US disclosed
US-20110009593-A1 Polymeric Bioplastics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-01-13 — — US disclosed
US-20110009593-A1 Polymeric Bioplastics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-01-13 — — US disclosed
WO-2009045719-A2 POLYMERIC BIOPLASTICS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-04-09 — — WO disclosed
WO-2009045719-A2 POLYMERIC BIOPLASTICS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-04-09 — — WO disclosed
US-20080289056-A1 CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES VERENIUM CORPORATION (US) 2008-11-20 — — US disclosed
US-7371759-B2 HMG-CoA reductase inhibitors and method BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131088-A1 TREATING CANCER WITH STATINS AND COMPOUNDS HAVING DIPYRIDAMOLE ACTIVITY HMGCR, DLD, DHFR SLC22A6 2010/4885GABRR1 1885/4885MAPT 4098/4885
US-20130296561-A1 PROCESS FOR THE PREPARATION OF STATINS IN THE PRESENCE OF BASE CYP4A11, HMGCR, PCSK9 SLC22A6 2100/4885GABRR1 4221/4885MAPT 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.